ADIPOQ polymorphism rs182052 is associated with clear cell renal cell carcinoma

Cancer Science

Volumn 106, Issue 6, 2015, Pages 687-691

  Zhang, Guiming ^a,b   Gu, Chengyuan ^a   Zhu, Yao ^a   Luo, Lei ^c   Dong, Dahai ^c   Wan, Fangning ^a   Zhang, Hailiang ^a   Shi, Guohai ^a   Sun, Lijiang ^c   Ye, Dingwei ^a,b  

^a FUDAN UNIVERSITY SHANGHAI CANCER CENTER   (China)

^b FUDAN UNIVERSITY   (China)

^c QINGDAO UNIVERSITY   (China)

Author keywords

Adiponectin; Case control study; Genetic susceptibility; Polymorphism; Renal cell carcinoma

Indexed keywords

ADIPONECTIN; ADIPOQ PROTEIN, HUMAN;

ADOLESCENT; ADULT; AGED; ALLELE; ARTICLE; CANCER RISK; CANCER STAGING; CASE CONTROL STUDY; CHINA; CONTROLLED STUDY; DIET RESTRICTION; DISEASE ASSOCIATION; FEMALE; GENE FREQUENCY; GENE LINKAGE DISEQUILIBRIUM; GENETIC VARIABILITY; GENOTYPE; HUMAN; KIDNEY CARCINOMA; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; OBESITY; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; BLOOD; GENETIC PREDISPOSITION; GENETICS; KIDNEY TUMOR; RISK; STATISTICAL MODEL; VERY ELDERLY;

ADIPONECTIN; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, RENAL CELL; CASE-CONTROL STUDIES; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; KIDNEY NEOPLASMS; LOGISTIC MODELS; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; RISK;

EID: 84930416176     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/cas.12664     Document Type: Article

References (44)

1. Siegel R, Ward E, Brawley O, Jemal A. Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin 2011; 61: 212-36.
2. Chow WH, Devesa SS. Contemporary epidemiology of renal cell cancer. Cancer J 2008; 14: 288-301.
3. Maestro ML, del Barco V, Sanz-Casla MT et al. Loss of heterozygosity on the short arm of chromosome 3 in renal cancer. Oncology 2000; 59: 126-30.
4. Barontini M, Dahia PL. VHL disease. Best Pract Res Clin Endocrinol Metab 2010; 24: 401-13.
5. Arjumand W, Ahmad ST, Seth A, Saini AK, Sultana S. Vitamin D receptor FokI and BsmI gene polymorphism and its association with grade and stage of renal cell carcinoma in North Indian population. Tumour Biol 2012; 33: 23-31.
6. Obara W, Suzuki Y, Kato K, Tanji S, Konda R, Fujioka T. Vitamin D receptor gene polymorphisms are associated with increased risk and progression of renal cell carcinoma in a Japanese population. Int J Urol 2007; 14: 483-7.
7. Karami S, Brennan P, Hung RJ et al. Vitamin D receptor polymorphisms and renal cancer risk in Central and Eastern Europe. J Toxicol Environ Health A 2008; 71: 367-72.
8. Lipworth L, Tarone RE, McLaughlin JK. The epidemiology of renal cell carcinoma. J Urol 2006; 176: 2353-8.
9. Chow WH, Gridley G, Fraumeni JF Jr, Jarvholm B. Obesity, hypertension, and the risk of kidney cancer in men. N Engl J Med 2000; 343: 1305-11.
10. Bergstrom A, Hsieh CC, Lindblad P, Lu CM, Cook NR, Wolk A. Obesity and renal cell cancer - a quantitative review. Br J Cancer 2001; 85: 984-90.
11. Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med 2003; 348: 1625-38.
12. Horiguchi A, Sumitomo M, Asakuma J et al. Increased serum leptin levels and over expression of leptin receptors are associated with the invasion and progression of renal cell carcinoma. J Urol 2006; 176: 1631-5.
13. Li L, Gao Y, Zhang LL, He DL. Concomitant activation of the JAK/STAT3 and ERK1/2 signaling is involved in leptin-mediated proliferation of renal cell carcinoma Caki-2 cells. Cancer Biol Ther 2008; 7: 1787-92.
14. Gavrila A, Chan JL, Yiannakouris N et al. Serum adiponectin levels are inversely associated with overall and central fat distribution but are not directly regulated by acute fasting or leptin administration in humans: cross-sectional and interventional studies. J Clin Endocrinol Metab 2003; 88: 4823-31.
15. Song M, Zhang X, Wu K et al. Plasma adiponectin and soluble leptin receptor and risk of colorectal cancer: a prospective study. Cancer Prev Res (Phila) 2013; 6: 875-85.
16. Macis D, Guerrieri-Gonzaga A, Gandini S. Circulating adiponectin and breast cancer risk: a systematic review and meta-analysis. Int J Epidemiol 2014; 43: 1226-36.
17. Luhn P, Dallal CM, Weiss JM et al. Circulating adipokine levels and endometrial cancer risk in the prostate, lung, colorectal, and ovarian cancer screening trial. Cancer Epidemiol Biomarkers Prev 2013; 22: 1304-12.
18. Kaklamani V, Yi N, Zhang K et al. Polymorphisms of ADIPOQ and ADIPOR1 and prostate cancer risk. Metabolism 2011; 60: 1234-43.
19. Cui E, Deng A, Wang X et al. The role of adiponectin (ADIPOQ) gene polymorphisms in the susceptibility and prognosis of non-small cell lung cancer. Biochem Cell Biol 2011; 89: 308-13.
20. Kaklamani VG, Wisinski KB, Sadim M et al. Variants of the adiponectin (ADIPOQ) and adiponectin receptor 1 (ADIPOR1) genes and colorectal cancer risk. JAMA 2008; 300: 1523-31.
21. Gornick MC, Rennert G, Moreno V, Gruber SB. Adiponectin gene and risk of colorectal cancer. Br J Cancer 2011; 105: 562-4.
22. Kaklamani VG, Sadim M, Hsi A et al. Variants of the adiponectin and adiponectin receptor 1 genes and breast cancer risk. Cancer Res 2008; 68: 3178-84.
23. Dhillon PK, Penney KL, Schumacher F et al. Common polymorphisms in the adiponectin and its receptor genes, adiponectin levels and the risk of prostate cancer. Cancer Epidemiol Biomarkers Prev 2011; 20: 2618-27.
24. Chen X, Xiang YB, Long JR et al. Genetic polymorphisms in obesity-related genes and endometrial cancer risk. Cancer 2012; 118: 3356-64.
25. Scherer PE, Williams S, Fogliano M, Baldini G, Lodish HF. A novel serum protein similar to C1q, produced exclusively in adipocytes. J Biol Chem 1995; 270: 26746-9.
26. Yamauchi T, Kamon J, Minokoshi Y et al. Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nat Med 2002; 8: 1288-95.
27. Kadowaki T, Yamauchi T. Adiponectin and adiponectin receptors. Endocr Rev 2005; 26: 439-51.
28. Kleinmann N, Duivenvoorden WC, Hopmans SN et al. Underactivation of the adiponectin-adiponectin receptor 1 axis in clear cell renal cell carcinoma: implications for progression. Clin Exp Metastasis 2014; 31: 169-83.
29. Sugiyama M, Takahashi H, Hosono K et al. Adiponectin inhibits colorectal cancer cell growth through the AMPK/mTOR pathway. Int J Oncol 2009; 34: 339-44.
30. Berg AH, Combs TP, Scherer PE. ACRP30/adiponectin: an adipokine regulating glucose and lipid metabolism. Trends Endocrinol Metab 2002; 13: 84-9.
31. Spyridopoulos TN, Petridou ET, Skalkidou A, Dessypris N, Chrousos GP, Mantzoros CS. Low adiponectin levels are associated with renal cell carcinoma: a case-control study. Int J Cancer 2007; 120: 1573-8.
32. Horiguchi A, Ito K, Sumitomo M, Kimura F, Asano T, Hayakawa M. Decreased serum adiponectin levels in patients with metastatic renal cell carcinoma. Jpn J Clin Oncol 2008; 38: 106-11.
33. Pinthus JH, Kleinmann N, Tisdale B et al. Lower plasma adiponectin levels are associated with larger tumor size and metastasis in clear-cell carcinoma of the kidney. Eur Urol 2008; 54: 866-73.
34. Liao LM, Schwartz K, Pollak M et al. Serum leptin and adiponectin levels and risk of renal cell carcinoma. Obesity (Silver Spring) 2013; 21: 1478-85.
35. Beebe-Dimmer JL, Zuhlke KA, Ray AM, Lange EM, Cooney KA. Genetic variation in adiponectin (ADIPOQ) and the type 1 receptor (ADIPOR1), obesity and prostate cancer in African Americans. Prostate Cancer Prostatic Dis 2010; 13: 362-8.
36. Moore SC, Leitzmann MF, Albanes D et al. Adipokine genes and prostate cancer risk. Int J Cancer 2009; 124: 869-76.
37. Teras LR, Goodman M, Patel AV et al. No association between polymorphisms in LEP, LEPR, ADIPOQ, ADIPOR1, or ADIPOR2 and postmenopausal breast cancer risk. Cancer Epidemiol Biomarkers Prev 2009; 18: 2553-7.
38. Purdue MP, Johansson M, Zelenika D et al. Genome-wide association study of renal cell carcinoma identifies two susceptibility loci on 2p21 and 11q13.3. Nat Genet 2011; 43: 60-5.
39. Wu X, Scelo G, Purdue MP et al. A genome-wide association study identifies a novel susceptibility locus for renal cell carcinoma on 12p11.23. Hum Mol Genet 2012; 21: 456-62.
40. Bryant EK, Dressen AS, Bunker CH et al. A multiethnic replication study of plasma lipoprotein levels-associated SNPs identified in recent GWAS. PLoS One 2013; 8: e63469.
41. Tang H, Dong X, Hassan M, Abbruzzese JL, Li D. Body mass index and obesity- and diabetes-associated genotypes and risk for pancreatic cancer. Cancer Epidemiol Biomarkers Prev 2011; 20: 779-92.
42. Neumann AS, Sturgis EM, Wei Q. Nucleotide excision repair as a marker for susceptibility to tobacco-related cancers: a review of molecular epidemiological studies. Mol Carcinog 2005; 42: 65-92.
43. Liu Y, Tong G, Tong W, Lu L, Qin X. Can body mass index, waist circumference, waist-hip ratio and waist-height ratio predict the presence of multiple metabolic risk factors in Chinese subjects? BMC Public Health 2011; 11: 35.
44. Riondino S, Roselli M, Palmirotta R, Della-Morte D, Ferroni P, Guadagni F. Obesity and colorectal cancer: role of adipokines in tumor initiation and progression. World J Gastroenterol 2014; 20: 5177-90.